Literature DB >> 24150871

Animal models of scleroderma: current state and recent development.

Yoshihide Asano1, Shinichi Sato.   

Abstract

Systemic sclerosis (SSc) is a multisystem connective tissue disease characterized by three cardinal features: immunological abnormalities, vasculopathy, and fibrosis of skin and certain internal organs. Although several animal models recapitulating selected aspects of SSc have been reported, the absence of models fulfilling the full clinical picture of SSc has hindered progress in the development and testing of therapy for this disease. In recent years, three new inducible animal models have revealed the critical importance of reactive oxygen species, angiotensin II, and the combination of DNA topoisomerase I immunization and IL-6 induction in fibrosis of SSc. In addition, two genetic animal models have revealed the potential involvement of transcription factors, Fra-2 and Fli1, in the fibrosis and vasculopathy of SSc. These new animal models provide important insights into specific pathological processes of SSc and novel therapeutic targets that may lead to more effective treatment of this incurable disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24150871     DOI: 10.1007/s11926-013-0382-7

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  80 in total

1.  Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway.

Authors:  J Czuwara-Ladykowska; F Shirasaki; P Jackers; D K Watson; M Trojanowska
Journal:  J Biol Chem       Date:  2001-03-16       Impact factor: 5.157

Review 2.  The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis.

Authors:  A L Herrick; M Matucci Cerinic
Journal:  Clin Exp Rheumatol       Date:  2001 Jan-Feb       Impact factor: 4.473

3.  COLLAGEN FIBRILS OF THE SCLERODERMA IN ULTRA-THIN SKIN SECTIONS.

Authors:  O BRAUN-FALCO; M RUPEC
Journal:  Nature       Date:  1964-05-16       Impact factor: 49.962

4.  Ets transcription factors cooperate with Sp1 to activate the human tenascin-C promoter.

Authors:  F Shirasaki; H A Makhluf; C LeRoy; D K Watson; M Trojanowska
Journal:  Oncogene       Date:  1999-12-16       Impact factor: 9.867

5.  EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).

Authors:  O Kowal-Bielecka; R Landewé; J Avouac; S Chwiesko; I Miniati; L Czirjak; P Clements; C Denton; D Farge; K Fligelstone; I Földvari; D E Furst; U Müller-Ladner; J Seibold; R M Silver; K Takehara; B Garay Toth; A Tyndall; G Valentini; F van den Hoogen; F Wigley; F Zulian; Marco Matucci-Cerinic
Journal:  Ann Rheum Dis       Date:  2009-01-15       Impact factor: 19.103

6.  The tight skin 2 mouse. An animal model of scleroderma displaying cutaneous fibrosis and mononuclear cell infiltration.

Authors:  P J Christner; J Peters; D Hawkins; L D Siracusa; S A Jiménez
Journal:  Arthritis Rheum       Date:  1995-12

Review 7.  TGF-beta1 and angiotensin networking in cardiac remodeling.

Authors:  Stephan Rosenkranz
Journal:  Cardiovasc Res       Date:  2004-08-15       Impact factor: 10.787

8.  An increased transforming growth factor beta receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor beta receptor type II in scleroderma.

Authors:  Jaspreet Pannu; Elizabeth Gore-Hyer; Masayoshi Yamanaka; Edwin A Smith; Semyon Rubinchik; Jian-Yun Dong; Stefania Jablonska; Maria Blaszczyk; Maria Trojanowska
Journal:  Arthritis Rheum       Date:  2004-05

9.  Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin.

Authors:  Masahide Kubo; Joanna Czuwara-Ladykowska; Omar Moussa; Margaret Markiewicz; Edwin Smith; Richard M Silver; Stefania Jablonska; Maria Blaszczyk; Dennis K Watson; Maria Trojanowska
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

10.  Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin.

Authors:  Yoshihide Asano; Margaret Markiewicz; Masahide Kubo; Gabor Szalai; Dennis K Watson; Maria Trojanowska
Journal:  Mol Cell Biol       Date:  2008-11-10       Impact factor: 4.272

View more
  11 in total

Review 1.  Critical Appraisal of the Utility and Limitations of Animal Models of Scleroderma.

Authors:  Kazuyuki Tsujino; Dean Sheppard
Journal:  Curr Rheumatol Rep       Date:  2016-01       Impact factor: 4.592

2.  Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice.

Authors:  Takashi Taniguchi; Yoshihide Asano; Kaname Akamata; Shinji Noda; Takehiro Takahashi; Yohei Ichimura; Tetsuo Toyama; Maria Trojanowska; Shinichi Sato
Journal:  Arthritis Rheumatol       Date:  2015-02       Impact factor: 10.995

3.  Transforming growth factor-β plays divergent roles in modulating vascular remodeling, inflammation, and pulmonary fibrosis in a murine model of scleroderma.

Authors:  Kazuyuki Tsujino; Nilgun Isik Reed; Amha Atakilit; Xin Ren; Dean Sheppard
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-11-18       Impact factor: 5.464

4.  Liver damage in bleomycin-induced pulmonary fibrosis in mice.

Authors:  V R Vásquez-Garzón; A Ramírez-Cosmes; E Reyes-Jiménez; G Carrasco-Torres; S Hernández-García; S R Aguilar-Ruiz; H Torres-Aguilar; J Alpuche; L Pérez-Campos Mayoral; S Pina-Canseco; J Arellanes-Robledo; S Villa-Treviño; R Baltiérrez-Hoyos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-07-16       Impact factor: 3.000

Review 5.  Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?

Authors:  Erica L Herzog; Aditi Mathur; Andrew M Tager; Carol Feghali-Bostwick; Frank Schneider; John Varga
Journal:  Arthritis Rheumatol       Date:  2014-08       Impact factor: 10.995

6.  Transforming growth factor-β signaling in systemic sclerosis.

Authors:  Nolan B Ayers; Chen-Ming Sun; Shi-You Chen
Journal:  J Biomed Res       Date:  2018-01-18

7.  A high-throughput sequence analysis of Japanese patients revealed 11 candidate genes associated with type 1 autoimmune pancreatitis susceptibility.

Authors:  Shugo Fujibayashi; Junpei Sasajima; Takuma Goto; Hiroki Tanaka; Hidemasa Kawabata; Tsuneshi Fujii; Kazumasa Nakamura; Atsushi Chiba; Nobuyuki Yanagawa; Kentaro Moriichi; Mikihiro Fujiya; Yutaka Kohgo
Journal:  Biochem Biophys Rep       Date:  2016-03-24

Review 8.  Mesenchymal stem cell as a novel approach to systemic sclerosis; current status and future perspectives.

Authors:  Mina Abedi; Sepideh Alavi-Moghadam; Moloud Payab; Parisa Goodarzi; Fereshteh Mohamadi-Jahani; Forough Azam Sayahpour; Bagher Larijani; Babak Arjmand
Journal:  Cell Regen       Date:  2020-12-01

9.  Pathogenesis of systemic sclerosis associated interstitial lung disease.

Authors:  Svetlana I Nihtyanova; Christopher P Denton
Journal:  J Scleroderma Relat Disord       Date:  2020-03-05

10.  MMP-12 deficiency attenuates angiotensin II-induced vascular injury, M2 macrophage accumulation, and skin and heart fibrosis.

Authors:  Lukasz Stawski; Paul Haines; Alan Fine; Lidia Rudnicka; Maria Trojanowska
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.